

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



China Health Group Limited
中國衛生集團有限公司

(Carrying on business in Hong Kong as CHG HS Limited)

(Incorporated in Bermuda with limited liability)

(Stock Code: 673)

SUSPENSION OF TRADING

The board (the “**Board**”) of directors (the “**Directors**”) of China Health Group Limited (the “**Company**”) hereby announces that trading in the shares of the Company on The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”) has been suspended at the request of the Company with effect from 9:00 a.m. on Wednesday, 2 July 2025, pending the publication of the audited annual results announcement for the year ended 31 March 2025 of the Company.

For details of the reason for the delay in publication of the audited annual results, please refer to the announcement dated 30 June 2025. Further announcement will be made by the Company as and when appropriate in accordance with the Rules Governing the Listing of Securities on the Stock Exchange.

By order of the Board

China Health Group Limited

Chung Ho

Chief Executive Officer and Executive Director

Hong Kong, 2 July 2025

As at the date of this announcement, the Board comprises three executive Directors, namely, Mr. Zhang Fan (chairman), Mr. Chung Ho and Mr. Xing Yong; two non-executive Directors, namely, Mr. Huang Lianhai and Mr. Wang Jingming; and four independent non-executive Directors, namely, Mr. Jiang Xuejun, Mr. Du Yanhua, Mr. Lai Liangquan and Ms. Yang Huimin.